Doctor Aya Shiraki

Doctor Aya Shiraki

Saga University, Saga (Japan)

Aya Shiraki is currently an Endowed Professor in Department of Geriatric Cardiovascular Diseases, Saga University School of Medicine. She received her M.D. from Saga University in 2002 and her Ph.D. in 2012. Her doctoral dissertation focused on the anti-inflammatory and antioxidant stress as favorable effects of liraglutide, a GLP-1 analog, in human endothelial cells. After her PhD, she continued her research in basic science related to cardiology, especially focusing on cardiac metabolism. In 2019, she published a paper showing that GLP-1 analogs alter the metabolic substrate (glucose/fat ratio) consumed by a failing heart, contributing to cardiac deterioration and improvement. She has published 13 peer-reviewed papers and one commentary paper.

Presentations

The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.

Event: ESC Congress 2022

Topic: Antidiabetic Pharmacotherapy

Session: Anti-diabetic pharmacotherapy in clinical practice

Access

Empagliflozin improves prognosis and energetic properties through modulating mitochondrial function in failing murine hearts

Event: ESC Congress 2021 - The Digital Experience

Topic: Experimental Heart Failure

Session: Novel therapies for heart failure in the early pipeline

Access

Doctor Aya Shiraki

Biography

Contributor content

The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.

Empagliflozin improves prognosis and energetic properties through modulating mitochondrial function in failing murine hearts

ESC 365 is supported by